Status:
UNKNOWN
Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Collaborating Sponsors:
Institut du Cancer de Montpellier - Val d'Aurelle
Conditions:
Cancer of Cervix
Apoptosis
Eligibility:
FEMALE
18+ years
Brief Summary
Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence ...
Detailed Description
Cervical cancer remains one of the most common cancers in women in terms of both incidence and mortality. Human Papilloma Virus carriage is a necessary condition for the development of these cancers b...
Eligibility Criteria
Inclusion
- Patients treated with the exclusive radio-chemotherapy combination for locally advanced cervical carcinoma (stage Ib-IVb according to FIGO classification).
- Patients aged ≥ 18 years.
- Patients with a minimum of 2 years post-treatment follow-up.
- Patients for whom the initial biopsy specimen (before treatment) is available.
- Patients who have not indicated that they do not wish to participate in the study.
- Patients affiliated to or benefiting from a health insurance scheme.
Exclusion
- Patients under court protection, guardianship or curatorship.
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2024
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT06147960
Start Date
November 1 2023
End Date
November 1 2024
Last Update
November 28 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.